Inhibrx Biosciences (NASDAQ:INBX) Director Buys $500,000.00 in Stock

Posted by Stanley Muller on Sep 26th, 2026

Inhibrx Biosciences, Inc. (NASDAQ:INBX – Get Free Report) Director Jon Kayyem acquired 5,000 shares of Inhibrx Biosciences stock in a transaction on Wednesday, September 23rd. The shares were purchased at an average cost of $100.00 per share, with a total value of $500,000.00. Following the completion of the acquisition, the director owned 434,360 shares of the company’s stock, valued at $43,436,000. This trade represents a 1.16% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Jon Faiz Kayyem also recently made the following trade(s):

On Wednesday, September 16th, Jon Kayyem bought 5,000 shares of Inhibrx Biosciences stock. The stock was purchased at an average cost of $100.00 per share, with a total value of $500,000.00.
On Tuesday, September 8th, Jon Kayyem bought 5,000 shares of Inhibrx Biosciences stock. The stock was purchased at an average price of $113.52 per share, for a total transaction of $567,600.00.

Inhibrx Biosciences Stock Performance

Shares of INBX opened at $99.61 on Friday. Inhibrx Biosciences, Inc. has a 1 year low of $28.16 and a 1 year high of $155.29. The company has a debt-to-equity ratio of 12.58, a current ratio of 5.07 and a quick ratio of 5.07. The stock’s fifty day moving average price is $101.24 and its two-hundred day moving average price is $95.41. The firm has a market cap of $1.47 billion, a PE ratio of -11.22 and a beta of 3.66.

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($2.34) earnings per share for the quarter, missing the consensus estimate of ($2.28) by ($0.06). On average, equities research analysts forecast that Inhibrx Biosciences, Inc. will post -9.91 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on INBX shares. Wall Street Zen lowered shares of Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a research report on Monday, August 17th. HC Wainwright assumed coverage on shares of Inhibrx Biosciences in a research note on Monday, August 24th. They set a “buy” rating and a $245.00 price target on the stock. Citigroup reaffirmed a “market perform” rating on shares of Inhibrx Biosciences in a report on Friday, September 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibrx Biosciences in a research note on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $197.50.

Check Out Our Latest Analysis on INBX

Hedge Funds Weigh In On Inhibrx Biosciences

Large investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC bought a new stake in Inhibrx Biosciences during the 2nd quarter worth approximately $31,000. Quantbot Technologies LP bought a new position in Inhibrx Biosciences in the 2nd quarter valued at $68,000. State of Wyoming bought a new position in Inhibrx Biosciences in the 2nd quarter valued at $116,000. Hurley Capital LLC purchased a new position in shares of Inhibrx Biosciences during the 4th quarter valued at $131,000. Finally, Seven Fleet Capital Management LP purchased a new position in shares of Inhibrx Biosciences during the 1st quarter valued at $167,000. 82.46% of the stock is currently owned by institutional investors.

Inhibrx Biosciences Company Profile

(Get Free Report)

Inhibrx Biosciences, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing biologic medicines for serious diseases with limited treatment options. The company uses a proprietary protein-engineering platform to design novel therapeutic proteins, including multivalent and long-acting biologics intended to selectively affect disease-related biological pathways.

Inhibrx’s development programs have included INBRX-101, also known as efzofitimod, an engineered fibroblast growth factor 1 intended for the treatment of alpha-1 antitrypsin deficiency-associated emphysema and other inflammatory lung conditions.